hard
believ
first
consist
report
acquir
immunodefici
syndrom
aid
year
ago
sinc
respiratori
gener
physician
becom
accustom
deal
extraordinari
rang
esoter
previous
unheard
condit
pneumocysti
carinii
known
pneumocysti
jirovecii
pneumonia
frequent
part
differenti
diagnosi
treatmentnonrespons
pneumon
ill
human
immunodefici
viru
hiv
test
almost
routin
offer
rule
test
clinic
case
defi
simpl
diagnosi
mani
part
develop
world
advanc
hiv
diseas
unfortun
likeliest
reason
seek
medic
care
chang
wrought
peopl
countri
economi
huge
depress
isol
hiv
patient
aid
mid
pave
way
intens
research
ultim
develop
drug
direct
chronic
infect
howev
despit
advanc
method
hiv
infect
lead
sever
immun
dysregul
clinic
diseas
still
fulli
defin
introduct
develop
world
highli
activ
antiretrovir
therapi
also
known
combin
antiretrovir
therapi
cart
hereto
refer
haart
alter
natur
histori
extraordinari
condit
haart
defin
combin
medic
usual
includ
least
three
potent
antihiv
agent
treatment
larg
consist
specif
opportunist
infect
manag
less
effect
antiretrovir
therapi
clinic
consequ
chang
enorm
rel
hazard
develop
pneumocysti
pneumonia
pcp
hivinfect
individu
fallen
drug
therapi
side
signific
unwant
effect
well
major
interact
medic
eg
rifamycin
use
treat
tuberculosi
profound
chang
immun
induc
haart
may
also
lead
diseas
immun
reconstitut
inflammatori
syndrom
iri
notwithstand
haart
respiratori
diseas
remain
import
caus
morbid
mortal
much
world
afford
medic
two
third
hivinfect
individu
least
one
respiratori
episod
cours
ill
earli
stage
hiv
infect
patient
rel
preserv
immun
respons
individu
infect
found
gener
popul
although
greater
incid
progress
hiv
diseas
subject
increas
risk
opportunist
diseas
exampl
north
american
prospect
studi
pulmonari
complic
hiv
infect
pspc
multicent
cohort
drawn
hiv
risk
group
variou
stage
immunosuppress
reveal
studi
period
approxim
subject
use
haart
report
upper
respiratori
tract
infect
episod
acut
bronchiti
acut
sinus
bacteri
pneumonia
pcp
develop
immun
dysregul
aris
hiv
infect
mean
bacteria
mycobacteria
fungi
virus
protozoa
caus
diseas
subject
advanc
infect
tabl
show
organ
typic
infect
lung
hiv
diseas
bacteri
infect
tuberculosi
pcp
import
west
aid
diagnos
due
pcp
chapter
provid
brief
gener
overview
epidemiolog
pathogenesi
hiv
infect
concentr
hiv
infecti
pulmonari
complic
report
end
million
individu
worldwid
acquir
hiv
infect
figur
thought
aid
develop
definit
aid
see
tabl
box
global
million
individu
acquir
hiv
infect
time
million
die
aid
develop
world
affect
subsaharan
africa
current
epicent
pandem
two
third
infect
one
five
adult
hiv
infect
south
southeast
asia
respons
almost
fifth
estim
hiv
global
burden
centraleastern
europ
central
asia
current
million
hivinfect
individu
develop
world
north
america
western
europ
account
approxim
million
infect
respect
spread
sexual
contact
although
vertic
mothertochild
bloodborn
infect
also
common
develop
world
heterosexu
transmiss
norm
howev
north
america
europ
homosexu
bisexu
men
constitut
largest
group
infect
individu
hiv
first
isol
patient
symptom
sign
immun
dysfunct
two
subtyp
subsequ
identifi
hereaft
refer
hiv
respons
infect
aggress
clinic
cours
focu
chapter
hiv
human
retroviru
belong
lentiviru
famili
cellfre
cellassoci
hiv
infect
attach
viral
envelop
protein
antigen
complex
host
cell
receptor
found
sever
cell
type
although
thelper
lymphocyt
main
site
hiv
infect
bodi
hiv
must
also
bind
cell
surfac
protein
coreceptor
call
chemokin
receptor
coreceptor
includ
depend
host
cell
type
polymorph
gene
may
affect
diseas
progress
reduc
abil
hiv
enter
infect
cell
howev
popul
level
effect
small
hiv
insid
cell
use
enzym
revers
transcriptas
rnadepend
dna
polymeras
transcrib
hiv
rna
dna
copi
transloc
nucleu
integr
host
cell
dna
use
viral
integras
viru
provir
dna
remain
latent
mani
cell
cell
becom
activ
may
aris
cytokin
antigen
stimul
viral
genet
materi
transcrib
new
rna
form
newli
creat
virion
bud
cell
surfac
free
infect
cell
hiv
infect
directli
attack
immun
system
particular
thelper
cell
central
coordin
immun
respons
lead
progress
immun
dysfunct
inabl
resist
opportunist
diseas
pathogen
process
well
defin
although
thought
time
primari
infect
hiv
spread
lymph
node
circul
immun
cell
thymu
massiv
viral
infect
human
host
although
seem
rel
potent
immun
respons
fact
initi
onslaught
devast
target
specif
memori
cell
respons
sustain
longterm
protect
immun
scene
set
progress
immun
failur
occur
combin
direct
cell
kill
hiv
replic
within
cell
well
neg
effect
chronic
immun
activ
ultim
lead
individu
immun
system
destruct
dysfunct
reflect
clinic
diseas
indic
profound
immunosuppress
also
measur
reduct
circul
absolut
cell
count
percentag
cell
express
marker
progress
reduct
tcell
ratio
use
haart
well
prevent
prophylact
therapi
opportunist
infect
chang
clinic
pictur
hiv
diseas
countri
intervent
avail
death
rate
fallen
one
sixth
previou
level
howev
absenc
treatment
median
interv
hiv
seroconvers
progress
aid
develop
world
estim
year
although
rather
less
resourcepoor
countri
almost
individu
aid
develop
untreat
without
haart
die
within
year
mani
part
world
main
caus
death
patient
hiv
infect
includ
bacteri
pneumonia
tuberculosi
pcp
cours
hiv
infect
divid
clinic
sever
distinct
period
acquisit
viru
seroconvers
without
clinic
ill
primari
hiv
infect
clinic
silent
period
last
sever
month
year
develop
symptom
sign
indic
degre
immunosuppress
aid
subject
opportunist
diseas
impli
profound
immunosuppress
eg
pcp
time
acquisit
hiv
infect
develop
detect
antibodi
window
period
usual
approxim
week
individu
becom
infect
seroconvers
ill
hiv
antibodi
normal
present
within
week
symptom
although
take
longer
hiv
rna
peripher
blood
detect
often
use
confirm
infect
nonspecif
featur
primari
hiv
infect
almost
alway
selflimit
typic
seroconvers
mimic
flulik
ill
glandular
fever
individu
primari
hiv
infect
recov
acut
symptom
within
week
proport
may
persist
symmetr
gener
lymphadenopathi
differ
prognosi
group
compar
asymptomat
hivposit
individu
although
proport
individu
remain
complet
well
without
treatment
extend
period
approxim
year
mani
hivinfect
individu
minor
symptom
sign
suggest
immun
dysfunct
exampl
includ
new
worsen
rash
includ
herp
simplex
tired
cough
lowgrad
anemia
certain
clinic
symptom
sign
provid
import
prognost
inform
studi
shown
oral
candidiasi
constitut
symptom
eg
malais
idiopath
fever
night
sweat
diarrhea
weight
loss
strongest
clinic
predictor
progress
aid
term
aid
creat
epidemiolog
tool
captur
condit
earli
hiv
epidem
seem
suggest
signific
immun
destruct
time
modifi
incorpor
expand
spectrum
recogn
diseas
affect
immunosuppress
individu
cervic
carcinoma
recurr
bacteri
pneumonia
see
box
center
diseas
control
prevent
cdc
classif
includ
immunolog
criterion
aid
count
cellsml
percentag
total
lymphocyt
regardless
clinic
symptom
see
tabl
data
use
defin
point
risk
sever
opportunist
infect
rise
dramat
exampl
seen
multicent
aid
cohort
studi
mac
homosexu
bisexu
men
without
aid
found
incid
pcp
subject
use
prophylaxi
rose
month
men
baselin
count
cellsml
count
cellsml
apart
cervic
carcinoma
aid
indic
diseas
differ
littl
men
women
inject
drug
user
high
incid
wast
syndrom
recurr
bacteri
pneumonia
tuberculosi
geograph
differ
diseas
occur
reflect
opportunist
pathogen
present
local
environ
eg
histoplasmosi
viscer
leishmaniasi
usual
occur
patient
endem
area
develop
world
sexual
racial
hiv
risk
factor
surviv
differ
aid
diagnosi
mainli
aris
variat
eas
access
medic
care
certainli
case
howev
better
treatment
outcom
associ
genuin
specialist
care
provid
peopl
extens
experi
field
countri
haart
avail
spectrum
hivrel
diseas
chang
eurosida
cohort
paneuropean
prospect
studi
hiv
infect
opportunist
infect
associ
low
count
eg
cytomegaloviru
cmv
retin
mycobacterium
aviumintracellular
complex
mac
infect
observ
less
frequent
time
malign
diseas
nonhodgkin
lymphoma
increas
aidsdefin
event
although
death
rate
fallen
haarttreat
popul
rise
proport
nonaid
death
seri
account
event
caus
includ
liver
diseas
often
caus
viral
hepat
cancer
well
cardiovascular
diseas
drugrel
toxic
circumst
aid
death
usual
occur
among
patient
access
medic
care
regularli
initi
seen
advanc
hiv
diseas
new
manifest
opportunist
infect
describ
patient
commenc
haart
immun
reconstitut
diseas
iri
may
caus
sever
temporari
clinic
ill
individu
immun
recov
patient
appear
develop
relaps
origin
partial
treat
diseas
often
seen
mac
infect
tuberculosi
hepat
b
cmv
retin
herpesvir
infect
metabol
complic
haart
ischem
heart
diseas
diabet
potenti
problem
hiv
practic
develop
world
signific
number
individu
take
haart
also
experi
drug
toxic
increas
number
patient
also
surviv
manifest
symptom
associ
chronic
hepat
b
c
infect
hivassoci
nephropathi
often
chronic
kidney
diseas
common
black
african
signific
caus
longterm
morbid
laboratori
marker
clinic
symptom
eg
oral
thrush
independ
reflect
immun
chang
lead
seriou
diseas
stage
system
develop
predict
risk
progress
sever
opportunist
diseas
aid
fall
absolut
blood
tlymphocyt
count
wide
use
prognost
marker
although
count
may
affect
number
factor
apart
hiv
includ
intercurr
infect
cigarett
smoke
exercis
time
day
laboratori
variat
percentag
cell
ratio
cell
stabl
measur
may
use
absolut
count
seem
vari
wide
visit
visit
measur
plasma
hiv
rna
viral
load
provid
import
prognost
inform
guid
therapi
suggest
longterm
outcom
particular
valu
subject
clinic
well
high
count
give
indic
expect
speed
clinic
progress
clear
frequenc
hivrel
respiratori
diseas
occur
pulmonari
immun
respons
profoundli
dysregul
howev
mechan
underli
fulli
explain
part
alter
aris
reflect
complex
interplay
system
deriv
hiv
circul
antigen
traffick
pulmonari
vasculatur
local
immun
cell
airborn
antigen
studi
investig
pulmonari
immun
respons
use
vitro
cell
cultur
system
seek
mimic
pulmonari
environ
case
bronchoscopi
bronchoalveolar
lavag
bal
recov
lung
cell
infect
individu
recent
perform
symptomat
patient
requir
bronchoscopi
diagnost
procedur
subject
gener
advanc
hiv
infect
often
take
number
differ
drug
includ
antiretrovir
may
number
differ
pathogen
caus
pulmonari
diseasewhich
influenc
immun
find
final
question
whether
bal
fluid
truli
repres
site
immun
respons
lung
parenchyma
remain
unclear
reason
report
data
interpret
care
individu
risk
respiratori
diseas
determin
medic
histori
eg
receipt
effect
prevent
antiretrovir
therapi
place
resid
travel
histori
eg
influenc
geographi
mycobacteri
fungal
diseas
state
host
immun
fall
blood
count
high
plasma
rna
viral
load
increas
chanc
respiratori
infect
increas
spectrum
potenti
organ
respons
infect
immunosuppress
individu
exampl
hivinfect
individu
count
cellsml
four
time
like
one
episod
bacteri
pneumonia
per
year
higher
cell
count
exot
organ
found
subject
low
count
includ
bacteria
rhodococcu
equi
nocardia
asteroid
fungi
aspergillu
speci
penicillium
marneffei
p
jirovecii
reflect
import
tcell
deplet
macrophag
dysfunct
loss
host
immun
process
confirm
anim
experi
among
hivinfect
patient
inject
drug
user
greatest
risk
develop
bacteri
pneumonia
tuberculosi
individu
previou
respiratori
episod
pcp
bacteri
pneumonia
seem
increas
risk
diseas
whether
relat
host
environment
factor
certain
although
seem
like
structur
lung
damag
abnorm
pulmonari
physiolog
would
part
contribut
argument
support
increas
rate
pneumonia
hivinfect
smoker
compar
nonsmok
recent
work
shown
chronic
obstruct
pulmonari
diseas
copd
lung
cancer
occur
frequent
among
hivinfect
individu
compar
gener
popul
given
larg
number
hivinfect
individu
smoke
heavili
press
need
target
popul
smoke
cessat
reinforc
associ
demonstr
studi
smoke
rapid
progress
first
aid
ill
death
present
mimic
bacteri
exacerb
chronic
obstruct
lung
diseas
patient
product
cough
fever
pathogen
commonli
identifi
similar
gener
popul
ie
streptococcu
pneumonia
haemophilu
influenza
howev
patient
advanc
diseas
may
infect
pseudomona
aeruginosa
staphylococcu
aureu
respons
appropri
antibiot
therapi
convent
dose
good
although
relaps
frequent
occur
bronchiectasi
increasingli
recogn
hivinfect
patient
advanc
hiv
diseas
low
lymphocyt
count
probabl
aris
secondari
recurr
bacteri
p
jirovecii
infect
diagnosi
often
made
highresolutionfinecut
comput
tomographi
ct
scan
preval
accur
determin
although
improv
surviv
opportunist
infect
hiv
diseas
like
increasingli
common
clinic
practic
pathogen
isol
patient
bronchiectasi
seen
bronchiti
addit
pseudomona
cepacia
moraxella
catarrhali
describ
communityacquir
bacteri
pneumonia
occur
frequent
hivinfect
patient
gener
popul
especi
common
hivinfect
inject
drug
user
spectrum
bacteri
pathogen
similar
nonhivinfect
individu
see
tabl
pneumonia
common
caus
follow
h
influenza
hivinfect
individu
pneumonia
pneumonia
frequent
bacterem
one
studi
rate
pneumococc
bacteremia
hivinfect
individu
time
hivneg
popul
recent
work
confirm
case
caus
hivrel
bacteri
pneumonia
typic
blood
cultur
increas
pickup
rate
hivposit
patient
widespread
use
haart
led
decreas
rate
bacteri
pneumonia
bacteremia
although
still
consider
higher
seen
nonhivinfect
popul
bacteri
pneumonia
similar
present
hivinfect
uninfect
individu
chest
radiograph
frequent
atyp
mimick
pcp
case
figur
contrast
radiograph
lobar
segment
consolid
may
also
seen
wide
rang
bacteri
organ
figur
includ
pneumonia
p
aeruginosa
h
influenza
mycobacterium
tuberculosi
pcp
may
also
present
lobar
segment
consolid
subject
advanc
hiv
diseas
low
lymphocyt
count
p
aeruginosa
aureu
also
caus
pneumonia
complic
bacteri
pneumonia
frequent
occur
pleural
effus
twice
like
hiv
infect
often
occur
aureu
infect
empyema
intrapulmonari
abscess
format
present
patient
inevit
mortal
rate
high
approxim
nocardia
asteroid
infect
report
patient
advanc
hiv
diseas
low
lymphocyt
count
widespread
use
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
pcp
may
reduc
incid
infect
clinic
present
often
indistinguish
bacteri
infect
chest
radiograph
appear
may
mimic
tuberculosi
see
later
upper
lobe
consolid
cavit
interstiti
infiltr
pleural
effus
hilar
lymphadenopathi
diagnosi
made
identif
organ
sputumb
fluid
lung
tissu
rhodococcu
equi
r
equi
usual
produc
pneumonia
patient
advanc
hiv
infect
contact
farm
anim
soil
field
barn
anim
hous
present
subacut
week
cough
dyspnea
fever
pleurit
chest
pain
chest
radiograph
typic
show
consolid
cavit
pleural
effus
common
diagnosi
usual
made
cultur
sputum
blood
bronchoscopi
bal
pleural
aspir
may
necessari
case
bartonella
hensela
b
hensela
gramneg
bacillu
caus
bacillari
angiomatosi
hivinfect
patient
clinic
cutan
lesion
may
mimic
kaposi
sarcoma
may
distinguish
demonstr
organ
tissu
warthinstarri
silver
stain
bacillari
angiomatosi
may
also
infect
lung
produc
endobronchi
red
violet
polypoid
angiomat
lesion
may
resembl
kaposi
sarcoma
biopsi
necessari
confirm
diagnosi
tuberculosi
hiv
infect
associ
least
increas
risk
individu
activ
tuberculosi
develop
compar
noninfect
subject
taken
togeth
abil
infect
immunosuppress
immunocompet
tuberculosi
perhap
therefor
singl
import
diseas
associ
hiv
infect
estim
least
million
individu
hivtuberculosi
coinfect
tuberculosi
major
caus
hivrel
morbid
mortal
also
major
driver
resourcerich
resourcepoor
countri
current
overal
increas
tuberculosi
rate
hiv
infect
endem
tuberculosi
control
popul
level
almost
imposs
treatment
infect
avail
unit
kingdom
mani
center
routin
offer
hiv
antibodi
test
patient
tuberculosi
regardless
risk
factor
hiv
infect
unit
state
cdc
recommend
hiv
test
routin
part
health
care
patient
age
access
medic
servic
advantag
individu
found
hiv
infect
given
haart
furthermor
strategi
modifi
highrisk
behavior
reduc
ongo
hiv
transmiss
may
offer
activ
tuberculosi
occur
stage
hiv
infect
unlik
almost
everi
hivrel
infect
may
despit
effect
antiretrovir
therapi
unit
state
unit
kingdom
european
countri
report
tuberculosi
hivinfect
nonhivinfect
individu
mandatori
clinic
diseas
hivinfect
patient
may
aris
sever
differ
way
reactiv
latent
tuberculosi
rapid
progress
pulmonari
infect
reinfect
exogen
sourc
pulmonari
diseas
common
present
clinic
manifest
relat
level
individu
cellmedi
immun
exampl
subject
earli
hiv
diseas
clinic
featur
similar
normal
adult
postprimari
diseas
tabl
symptom
typic
includ
weight
loss
fever
sweat
cough
sputum
dyspnea
hemoptysi
chest
pain
patient
may
clinic
featur
suggest
associ
hiv
infect
chest
radiograph
frequent
show
upper
lobe
consolid
cavitari
chang
common
figur
tuberculin
skin
test
purifi
protein
deriv
ppd
usual
posit
likelihood
spontan
expector
sputum
bal
fluid
smear
posit
acidfast
bacilli
high
individu
advanc
hiv
diseas
ie
low
lymphocyt
count
clinic
appar
immunosuppress
may
difficult
diagnos
tuberculosi
clinic
present
often
nonspecif
symptom
fever
weight
loss
fatigu
malais
may
mistakenli
ascrib
hiv
infect
context
pulmonari
tuberculosi
often
similar
primari
infect
chest
radiograph
show
diffus
militarytyp
shadow
figur
hilar
mediastin
lymphadenopathi
pleural
effus
cavit
unusu
patient
chest
radiograph
may
appear
normal
other
pulmonari
infiltr
bilater
diffus
interstiti
pattern
thu
mimick
pcp
hilar
lymphadenopathi
pleural
effus
may
also
produc
pulmonari
kaposi
sarcoma
lymphoma
tuberculosi
may
coexist
tuberculin
skin
test
usual
neg
spontan
expector
sputum
bal
fluid
often
smear
neg
cultur
posit
addit
pulmonari
tuberculosi
extrapulmonari
diseas
occur
high
proport
hivinfect
individu
low
lymphocyt
count
cellsml
mycobacteremia
lymph
node
infect
figur
common
involv
bone
marrow
liver
pericardium
mening
brain
also
occur
evid
extrapulmonari
tuberculosi
sought
hivinfect
patient
suspect
confirm
pulmonari
tuberculosi
cultur
stool
urin
blood
bone
marrow
tradit
solid
phase
cultur
speciat
techniqu
may
take
week
liquid
cultur
method
eg
bactec
becton
dickinson
detect
earli
growth
may
provid
diagnosi
week
molecular
diagnost
test
use
tuberculosi
genom
detect
eg
polymeras
chain
reaction
pcr
offer
possibl
yet
rapid
diagnosi
within
hour
yet
routin
clinic
use
also
less
use
primari
sampl
low
bacteri
load
eg
smear
neg
sputum
often
need
hivcoinfect
patient
recent
descript
simpl
highli
sensit
specif
method
use
inocul
larg
quantiti
exampl
sputum
onto
microscop
plate
subsequ
rapid
detect
day
mycobacteri
growth
resist
pattern
mod
great
potenti
signific
result
cultur
speciat
known
acidfast
bacilli
identifi
respiratori
sampl
biopsi
tissu
aspir
blood
hivinfect
individu
regardless
lymphocyt
count
regard
tuberculosi
convent
antituberculosi
therapi
commenc
cultur
fail
demonstr
tuberculosi
instead
anoth
mycobacterium
see
later
identifi
treatment
modifi
multipl
drugresist
mdr
tuberculosisthat
tuberculosi
resist
isoniazid
rifampicin
rifampin
without
drug
import
clinic
problem
hivinfect
individu
unit
state
respons
approxim
tuberculosi
hivinfect
patient
outbreak
mdr
tuberculosi
occur
hivinfect
nonhivinfect
individu
unit
state
prison
facil
hostel
hospit
similar
outbreak
also
document
among
hivinfect
patient
europ
inadequ
treatment
includ
case
manag
supervis
medic
tuberculosi
poor
patient
complianc
antituberculosi
therapi
import
risk
factor
develop
mdr
tuberculosi
case
arisen
exogen
reinfect
profoundli
immunosuppress
hivinfect
patient
alreadi
receiv
treatment
drugsensit
diseas
despit
antituberculosi
therapi
median
surviv
hivinfect
individu
mdrtuberculosi
initi
month
recent
improv
larg
increas
awar
condit
earli
initi
suitabl
therapi
determin
drug
sensit
test
extens
drugresist
xdr
tuberculosisthat
tuberculosi
resist
isoniazid
rifampicin
rifampin
plu
fluoroquinolon
one
three
inject
secondlin
drug
capreomycin
kanamycin
amikacin
increasingli
import
clinic
problem
origin
describ
south
africa
associ
hiv
infect
xdr
tuberculosi
also
identifi
part
world
march
countri
report
least
one
case
although
mani
place
test
fluoroquinolon
sensit
standard
practic
number
may
fact
huge
underestim
concern
xdr
tuberculosi
despit
specif
therapi
mortal
high
among
hivinfect
individu
current
pictur
seem
mirror
earli
report
mdr
tuberculosi
hiv
infect
origin
south
african
studi
kwazulu
natal
surviv
less
week
time
receipt
first
sputum
sampl
mycobacterium
aviumintracellular
complex
widespread
avail
haart
dissemin
mac
infect
develop
hivinfect
patient
remain
problem
patient
advanc
hiv
diseas
receiv
antiretrovir
therapi
lymphocyt
count
cellsml
clinic
present
nonspecif
may
confus
effect
hiv
fever
night
sweat
weight
loss
anorexia
malais
common
anemia
hepatosplenomegali
abdomin
pain
chronic
diarrhea
frequent
find
diagnosi
dissemin
mac
infect
base
cultur
organ
blood
bone
marrow
lymph
node
liver
biopsi
specimen
also
mac
frequent
identifi
bal
fluid
sputum
stool
urin
detect
organ
site
diagnost
dissemin
infect
evid
pulmonari
mac
infect
usual
obtain
chest
radiograph
may
neg
show
nonspecif
infiltr
rare
focal
consolid
nodular
infiltr
apic
cavit
resembl
tuberculosi
report
mycobacterium
kansasii
mycobacterium
kansasii
second
common
nontubercul
opportunist
mycobacteri
infect
hivinfect
individu
usual
appear
late
cours
hiv
infect
patient
lymphocyt
count
cellsml
frequent
present
fever
cough
dyspnea
approxim
two
third
kansasii
infect
diseas
local
lung
remaind
dissemin
diseas
affect
bone
marrow
lymph
node
skin
lung
diagnosi
made
cultur
organ
respiratori
secret
bone
marrow
lymph
node
aspir
skin
biopsi
focal
upper
lobe
infiltr
diffus
interstiti
infiltr
common
radiograph
abnorm
thinwal
cavitari
lesion
hilar
adenopathi
also
report
mycobacterium
xenopi
mycobacterium
xenopi
may
occasion
isol
sputum
bal
fluid
sampl
signific
uncertain
patient
low
count
xenopi
usual
accompani
isol
copathogen
p
jirovecii
treatment
latter
condit
associ
case
resolut
symptom
evid
start
haart
prevent
diseas
recurr
provid
adequ
immun
respons
pneumocysti
jirovecii
pneumonia
develop
pcp
larg
relat
underli
state
immunosuppress
induc
malign
treatment
thereof
organ
transplant
hiv
infect
unit
state
unit
kingdom
europ
australasia
pcp
larg
seen
hivinfect
individu
unawar
serostatu
intoler
noncompli
antip
jirovecii
prophylaxi
haart
recent
p
jirovecii
regard
taxonom
protozoan
basi
morpholog
lack
respons
antifung
agent
amphotericin
b
organ
ascrib
fungal
kingdom
demonstr
antibodi
p
jirovecii
healthi
childrenadult
suggest
organ
acquir
childhood
persist
lung
dormant
phase
subsequ
immunosuppress
eg
result
hiv
infect
allow
fungu
propag
lung
caus
clinic
diseas
howev
latenc
hypothesi
challeng
sever
observ
p
jirovecii
identifi
lung
immunocompet
individu
case
cluster
pcp
health
care
facil
suggest
recent
transmiss
differ
genotyp
p
jirovecii
identifi
episod
hivinfect
patient
recurr
pcp
genotyp
p
jirovecii
patient
pcp
correl
place
diagnosi
place
birthsuggest
infect
recent
acquir
taken
togeth
data
suggest
pcp
aris
reinfect
exogen
sourc
clinic
present
pcp
nonspecif
onset
progress
exert
dyspnea
day
week
togeth
dri
cough
without
expector
minim
quantiti
mucoid
sputum
patient
often
complain
inabl
take
deep
breath
due
pleurisi
tabl
fever
common
yet
patient
rare
complain
temperatur
sweat
hivinfect
patient
present
usual
insidi
patient
receiv
immunosuppress
therapi
median
time
diagnosi
onset
symptom
week
hiv
compar
less
week
nonhivinfect
patient
small
proport
hivposit
individu
diseas
cours
pcp
fulmin
interv
day
onset
symptom
progress
develop
respiratori
failur
other
may
much
indol
respiratori
symptom
worsen
almost
impercept
sever
month
rare
pcp
may
present
without
respiratori
symptom
fever
undetermin
origin
clinic
examin
usual
remark
absenc
physic
sign
occasion
fine
basal
endinspiratori
crackl
audibl
featur
would
suggest
altern
diagnosi
includ
cough
product
purul
sputum
hemoptysi
chest
pain
particularli
pleural
pain
sign
focal
consolid
pleural
effus
see
tabl
note
infect
one
pathogen
occur
almost
one
fifth
individu
thu
symptom
may
product
sever
agent
chest
radiograph
pcp
typic
unremark
initi
later
diffus
reticular
shadow
especi
perihilar
region
seen
may
progress
diffus
alveolar
consolid
resembl
pulmonari
edema
untreat
patient
seen
late
diseas
stage
lung
may
massiv
consolid
almost
airless
figur
chest
radiograph
atyp
show
lobar
consolid
honeycomb
lung
multipl
thinwal
cystic
air
space
format
pneumatocel
intrapulmonari
nodul
cavitari
lesion
pneumothorax
hilar
mediastin
lymphadenopathi
predominantli
apic
chang
resembl
tuberculosi
may
occur
patient
pcp
develop
receiv
antip
jirovecii
prophylaxi
nebul
pentamidin
figur
radiograph
chang
chest
radiograph
earli
perihilar
haze
bilater
interstiti
shadow
late
alveolarinterstiti
chang
white
mark
alveolar
consolid
spare
apic
costophren
angl
arteri
blood
gase
pao
earli
normal
late
low
paco
earli
normal
low
late
normal
high
nonspecif
similar
chang
occur
pulmonari
pathogen
includ
pyogen
bacteri
mycobacteri
fungal
infect
well
kaposi
sarcoma
nonspecif
interstiti
pneumon
respiratori
symptom
immunosuppress
hivinfect
individu
neg
chest
radiograph
discount
interv
day
radiograph
abnorm
may
appear
diagnosi
pcp
made
demonstr
organ
induc
sputum
bal
fluid
lung
biopsi
materi
use
histochem
immunofluoresc
techniqu
earli
promis
molecular
diagnost
techniqu
born
mani
fungal
infect
lung
confin
specif
geograph
region
although
widespread
travel
may
present
patient
outsid
area
candida
aspergillu
cryptococcu
speci
ubiquit
occur
worldwid
contrast
infect
oropharynx
esophagu
candid
infect
trachea
bronchi
lung
rare
hivinfect
patient
candidemia
dissemin
candidiasi
deep
focal
candidiasi
clinic
present
pulmonari
candid
infect
specif
featur
chest
radiographi
equal
nonspecificit
may
neg
show
patchi
infiltr
isol
candida
sputum
may
simpli
repres
colon
mean
patient
candid
pneumonia
indirect
evid
may
obtain
posit
cultur
rise
antibodi
titer
howev
hivinfect
patient
high
antibodi
titer
alon
less
reliabl
indic
antibodi
may
absent
proven
case
invas
candid
infect
correl
occur
identif
larg
quantiti
candida
speci
bal
fluid
candida
speci
caus
pneumonia
definit
diagnosi
made
lung
biopsi
contrast
patient
immunosuppress
render
neutropen
system
chemotherapi
infect
aspergillu
speci
rel
rare
hivposit
individu
risk
factor
aspergillosi
neutropenia
commonli
drug
induc
zidovudin
ganciclovir
patient
receipt
corticosteroid
fever
cough
dyspnea
common
present
symptom
pleurit
chest
pain
hemoptysi
found
approxim
one
third
patient
pattern
pulmonari
diseas
includ
cavit
upper
lobe
diseas
focal
radiograph
opac
resembl
bacteri
pneumonia
bilater
diffus
patchi
opac
nodular
reticularnodular
pattern
pseudomembran
aspergillosi
may
obstruct
lumen
airway
tracheobronch
diagnosi
pulmonari
aspergillosi
made
identif
fungu
sputum
sputum
cast
bal
fluid
associ
respiratori
tract
tissu
invas
figur
role
antigen
test
galactomannan
assay
commonplac
hematolog
patient
risk
invas
aspergillu
clearli
defin
hivinfect
individu
infect
may
present
one
two
way
either
primari
cryptococcosi
complic
cryptococc
mening
part
dissemin
infect
cryptococcemia
pneumonia
cutan
diseas
umbil
papul
mimick
molluscum
contagiosum
figur
primari
pulmonari
cryptococcosi
present
nonspecif
way
frequent
indistinguish
pulmonari
infect
dissemin
infect
present
frequent
overshadow
headach
fever
malais
caus
mening
durat
onset
may
rang
day
sever
week
examin
may
reveal
skin
lesion
lymphadenopathi
mening
chest
sign
may
absent
crackl
may
audibl
arteri
blood
ga
tension
may
normal
show
hypoxemia
common
abnorm
chest
radiograph
focal
diffus
interstiti
infiltr
less
frequent
mass
mediastin
hilar
lymphadenopathi
nodul
effus
note
diagnosi
cryptococc
pulmonari
infect
figur
made
identif
cryptococcu
neoforman
stain
india
ink
mucicarmin
cultur
sputum
bal
fluid
pleural
fluid
lung
biopsi
cryptococc
antigen
may
detect
serum
use
cryptococc
latex
agglutin
crag
test
titer
usual
high
may
neg
primari
pulmonari
cryptococcosi
case
bal
fluid
crag
posit
patient
dissemin
infect
c
neoforman
may
also
cultur
blood
cerebrospin
fluid
mortal
rate
high
dissemin
form
endem
mycos
caus
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
found
hivinfect
patient
live
north
america
especi
mississippi
ohio
river
valley
histoplasmosi
also
found
southeast
asia
caribbean
island
south
america
coccidioidomycosi
endem
southwest
unit
state
southern
california
northern
mexico
part
argentina
brazil
blastomycosi
similar
distribut
extens
north
canada
progress
dissemin
histoplasmosi
patient
hiv
typic
present
subacut
onset
fever
weight
loss
approxim
patient
mild
respiratori
symptom
nonproduct
cough
dyspnea
hepatosplenomegali
frequent
found
examin
rash
similar
produc
cryptococcu
speci
may
seen
rare
present
may
rapidli
fulmin
clinic
featur
sepsi
syndrom
includ
anemia
dissemin
intravascular
coagul
chest
radiograph
may
unremark
one
third
patient
although
characterist
abnorm
bilater
widespread
nodul
mm
size
radiograph
featur
nonspecif
includ
interstiti
infiltr
reticular
nodular
shadow
alveolar
consolid
histoplasmosi
may
dissemin
central
nervou
system
produc
meningoenceph
mass
lesion
diagnosi
made
reliabl
identif
organ
wrightstain
peripher
blood
giemsa
stain
bone
marrow
lymph
node
skin
sputum
bal
fluid
lung
tissu
import
identif
confirm
detect
h
capsulatum
var
capsulatum
polysaccharid
antigen
radioimmunoassay
high
sensit
falseposit
result
may
occur
patient
infect
blastomycosi
coccidioid
speci
test
histoplasma
antibodi
complement
fixat
immunodiffus
may
neg
immunosuppress
hivposit
patient
clinic
present
coccidioidomycosi
variabl
chest
radiograph
may
show
focal
pulmonari
diseas
focal
alveolar
infiltr
adenopathi
intrapulmonari
caviti
altern
diffus
reticular
infiltr
diagnosi
made
isol
organ
sputum
bal
fluid
dissemin
diseas
identifi
isol
fungu
blood
urin
cerebrospin
fluid
serolog
test
may
also
use
diagnosi
blastomycosi
present
patient
advanc
hiv
infect
lymphocyt
count
usual
less
cellsml
clinic
symptom
includ
cough
fever
dyspnea
weight
loss
patient
may
present
late
respiratori
failur
dissemin
diseas
occur
pulmonari
extrapulmonari
featur
frequent
multipl
involv
skin
liver
brain
mening
chest
radiograph
abnorm
includ
focal
pneumon
chang
miliari
shadow
diffus
interstiti
infiltr
diagnosi
made
cultur
bal
fluid
skin
blood
infect
cytolog
histolog
diagnosi
import
earli
diagnosi
cultur
organ
may
take
week
mortal
rate
high
patient
dissemin
infect
p
marneffei
infect
particularli
common
southeast
asia
hivinfect
patient
present
dissemin
infect
solitari
skin
oral
mucos
lesion
multipl
infiltr
liver
spleen
bone
marrow
lead
present
pancytopenia
pulmonari
infect
specif
clinic
featur
chest
radiograph
may
neg
show
diffus
small
nodular
infiltr
diagnosi
made
identifi
organ
bone
marrow
skin
biopsi
sampl
blood
film
bal
fluid
differenti
diagnosi
p
marneffei
infect
includ
pcp
tuberculosi
occur
equal
frequenc
hivinfect
nonhivinfect
patient
howev
respiratori
complic
influenza
infect
increas
patient
affect
underli
condit
cardiac
pulmonari
diseas
immunosuppress
prospect
studi
hivinfect
patient
undergo
bronchoscopi
evalu
suspect
lower
respiratori
tract
diseas
communityacquir
respiratori
viral
infect
ie
influenza
parainfluenza
respiratori
syncyti
viru
rhinoviru
coronaviru
adenoviru
found
rare
cmv
chronic
infect
hivinfect
individu
homosexu
hivinfect
men
shed
cmv
intermitt
urin
semen
saliva
clinic
diseas
may
caus
cmv
patient
advanc
hiv
infect
count
cellsml
chorioretin
frequent
encount
enceph
adren
esophag
coliti
also
seen
frequent
cmv
isol
bal
fluid
found
sampl
patient
count
cellsml
howev
role
cmv
caus
diseas
context
unclear
see
later
patient
cmv
sole
identifi
pathogen
clinic
present
chest
radiograph
abnorm
usual
diffus
interstiti
infiltr
nonspecif
diagnosi
cmv
pneumon
made
identifi
characterist
intranuclear
intracytoplasm
inclus
cell
bal
fluid
also
lung
biopsi
specimen
figur
pulmonari
involv
leishmania
speci
may
rare
occur
part
syndrom
viscer
leishmaniasi
hivinfect
patient
patient
usual
advanc
hiv
diseas
lymphocyt
count
less
cellsml
present
unexplain
fever
splenomegali
leukopenia
respiratori
symptom
often
absent
diagnosi
viscer
leishmaniasi
often
made
stain
splenic
bone
marrow
aspir
subsequ
cultur
occasion
parasit
found
chanc
skin
rectal
biopsi
bal
fluid
taken
purpos
chest
radiograph
may
neg
show
reticularnodular
infiltr
toxoplasma
gondii
infect
patient
aid
usual
occur
result
reactiv
latent
intracellular
protozoa
acquir
primari
infect
patient
invari
system
unwel
malais
pyrexia
clinic
diseas
associ
hiv
infect
commonli
seen
central
nervou
system
produc
singl
multipl
abscess
multisystem
infect
gondii
uncommon
patient
hiv
infect
toxoplasm
pneumonia
frequent
difficult
distinguish
pcp
nonproduct
cough
dyspnea
symptom
commonli
report
chest
radiograph
abnorm
includ
diffus
interstiti
infiltr
indistinguish
pcp
figur
well
micronodular
infiltr
coars
nodular
infiltr
cavitari
chang
lobar
consolid
diagnosi
made
hematoxylineosin
giemsa
stain
bal
fluid
reveal
cyst
trophozoit
gondii
stain
bal
fluid
alway
posit
diagnost
yield
increas
either
stain
transbronchi
biopsi
materi
perform
nucleic
acid
amplif
procedur
pcr
detect
gondii
dna
bal
fluid
frequent
manifest
infect
cryptosporidium
speci
hiv
infect
noninflammatori
diarrhea
may
high
volum
intract
life
threaten
cryptosporidium
speci
may
colon
epitheli
surfac
includ
trachea
lung
occasion
result
pulmonari
infect
case
pulmonari
cryptosporidiosi
copatholog
pcp
bacteri
pneumonia
ascertain
exact
role
cryptosporidiosi
caus
respiratori
symptom
may
difficult
diagnosi
made
ziehlneelsen
auraminerhodamin
stain
bal
fluid
transbronchi
biopsi
specimen
pulmonari
microsporidia
infect
may
occur
part
system
dissemin
gastrointestin
infect
septata
intestinali
encephalitozoon
hellem
organ
may
identifi
convent
stain
bal
fluid
electron
microscopi
necessari
distinguish
two
speci
nematod
strong
yloid
stercorali
endem
warm
countri
worldwid
immunosuppress
patient
organ
increas
abil
reproduc
parthenogenet
gastrointestin
tract
without
need
repeat
exposur
new
infectionsocal
autoinfect
result
great
increas
worm
load
hyperinfect
state
ensu
massiv
acut
dissemin
stercorali
may
occur
lung
kidney
pancrea
brain
although
infect
stercorali
sever
immunocompromis
patient
common
patient
hiv
infect
present
hyperinfect
may
fever
hypotens
secondari
bacteri
sepsi
dissemin
intravascular
coagul
clinic
featur
respiratori
stercorali
infect
nonspecif
stercorali
sputum
bal
fluid
figur
may
identifi
hivposit
patient
absenc
symptom
elsewher
predat
dissemin
infect
requir
prompt
treatment
appar
forego
discuss
hivrel
pneumonia
caus
may
present
similar
manner
wide
rang
investig
avail
aid
diagnosi
list
tabl
subject
produc
sputum
import
obtain
sampl
bacteri
mycobacteri
detect
one
third
case
assist
diagnosi
three
sampl
consecut
day
prefer
either
overnight
earli
morn
product
critic
first
step
diagnosi
pulmonari
tuberculosi
consider
easier
safer
health
care
personnel
obtain
hyperton
salineinduc
sputum
bal
fluid
blood
cultur
also
import
high
rate
bacteremia
report
bacteri
mycobacteri
diseas
see
earlier
patient
initi
seen
symptom
sign
consist
pneumonia
chest
radiographi
arteri
oxygen
assess
perform
first
consult
question
stage
usual
whether
infecti
episod
due
bacteri
infect
tuberculosi
pcp
gener
alveolar
interstiti
shadow
taken
evid
pcp
although
import
caveat
appli
transcutan
puls
oximetri
arteri
blood
ga
analysi
use
test
hypoxemia
use
distinguish
alveolar
condit
ie
pcp
bacteri
pneumonia
alveol
produc
greater
impair
oxygen
transfer
especi
exercis
given
clinic
situat
hypoxemia
wider
alveolararteri
oxygen
gradient
aao
pcp
puls
oximetri
manifest
low
oxygen
satur
rest
decreas
exercis
gener
inform
obtain
arteri
blood
ga
analysi
although
advantag
offset
need
direct
arteri
punctur
patient
pcp
fewer
normal
pao
normal
aao
measur
sensit
although
particularli
specif
pcp
similar
result
may
occur
bacteri
pneumonia
pulmonari
kaposi
sarcoma
tuberculosi
infect
diagnost
valu
identifi
exerciseinduc
desatur
measur
transcutan
oximetri
valid
hivinfect
patient
pcp
normal
near
normal
appear
chest
radiograph
test
valu
confirm
patient
abnorm
chest
radiograph
pcp
pathogen
exerciseinduc
desatur
may
persist
mani
week
treatment
recoveri
pcp
even
absenc
activ
pulmonari
diseas
abnorm
lung
function
well
document
hiv
infect
common
relat
test
measur
ga
exchang
rather
size
conduct
airway
gener
overal
reduct
diffus
capac
carbon
monoxid
dlco
occur
stage
hiv
infect
largest
chang
found
hivinfect
patient
pcp
thu
extent
patient
probabl
pcp
differenti
treatment
guid
normal
dlco
individu
symptom
neg
unchang
chest
radiograph
make
diagnosi
pcp
extrem
unlik
data
north
american
pspc
cohort
studi
suggest
individu
rapid
rate
declin
dlco
increas
risk
develop
pcp
recent
work
suggest
hivinfect
smoker
increas
risk
earlyonset
emphysema
smoke
histori
must
therefor
taken
account
assess
patient
lung
function
result
context
possibl
pcp
highresolut
finecut
ct
scan
chest
may
help
chest
radiograph
normal
unchang
equivoc
characterist
appear
alveol
ie
area
groundglass
attenu
pulmonari
vessel
clearli
identifi
may
present
indic
activ
pulmonari
diseas
figur
featur
howev
neither
sensit
specif
pcp
although
sensit
improv
evid
reticul
andor
small
cystic
lesion
ad
henc
neg
test
result
impli
altern
diagnosi
context
hivinfect
patient
seen
acut
subacut
pneumon
elev
serum
lactat
dehydrogenas
ldh
enzym
level
strongli
suggest
pcp
interpret
result
import
rememb
pulmonari
diseas
process
eg
pulmonari
embol
nonspecif
pneumon
bacteri
mycobacteri
pneumonia
extrapulmonari
diseas
castleman
diseas
lymphoma
may
also
caus
elev
ldh
may
need
consid
correct
clinic
context
previou
inform
evid
noninvas
test
reliabl
distinguish
differ
infect
agent
may
use
exclud
acut
opportunist
diseas
thu
clinician
left
either
proceed
diagnost
lung
fluid
tissu
sampl
either
induc
sputum
collect
bronchoscopi
bal
without
transbronchi
biopsi
tabl
treat
unknown
condit
empir
haart
also
alter
investig
respiratori
diseas
number
invas
procedur
perform
fall
tend
patient
spontan
expector
sputum
inadequ
diagnosi
pcp
sputum
induct
inhal
ultrason
nebul
hyperton
salin
may
provid
suitabl
specimen
see
tabl
techniqu
requir
close
attent
detail
much
less
use
sampl
purul
sputum
induct
must
carri
away
immunosuppress
patient
health
care
worker
ideal
room
separ
negativepressur
ventil
reduc
risk
nosocomi
transmiss
tuberculosi
although
specif
sensit
induc
sputum
vari
wide
therefor
neg
result
p
jirovecii
prompt
diagnost
studi
use
immunofluoresc
stain
enhanc
yield
induc
sputum
compar
standard
cytochemistri
fiberopt
bronchoscopi
bal
commonli
use
diagnos
hivrel
pulmonari
diseas
good
wedg
sampl
obtain
test
sensit
detect
p
jirovecii
figur
induc
sputum
fluoresc
stain
method
increas
diagnost
yield
make
procedur
choic
center
technic
demand
patient
oper
induc
sputum
collect
bronchoscopi
bal
advantag
direct
inspect
upper
airway
bronchial
tree
perform
necessari
biopsi
taken
transbronchi
biopsi
may
margin
increas
diagnost
yield
procedur
relev
diagnosi
mycobacteri
diseas
although
rel
high
complic
rate
hivinfect
individu
pneumothorax
possibl
signific
pulmonari
hemorrhag
outweigh
advantag
techniqu
routin
purpos
sampl
bal
fluid
examin
bacteria
mycobacteria
virus
fungi
protozoa
inspect
cellular
compon
may
also
provid
etiolog
cluescooper
patholog
depart
experi
opportunist
infect
diagnosi
vital
drug
interact
associ
antiretrovir
proteas
inhibitor
pi
therapi
mean
special
care
exercis
sedat
use
either
benzodiazepin
opiat
drug
prolong
sedat
lifethreaten
arrhythmia
report
diagnost
strategi
therefor
includ
sputum
induct
result
nondiagnost
test
unavail
bronchoscopi
bal
yield
result
consider
given
either
repeat
bronchoscopi
bal
transbronchi
biopsi
surgic
biopsi
latter
perform
either
open
lung
thoracoscop
procedur
surgic
biopsi
high
sensit
although
empir
therapi
usual
reserv
manag
presum
bacteri
pneumonia
first
sight
may
seem
unwis
deal
possibl
opportunist
infect
realiti
pcp
almost
invari
diagnosi
exclus
certain
clinic
laboratori
featur
may
guid
assess
hivinfect
individu
risk
condit
likelihood
p
jirovecii
caus
organ
increas
subject
take
effect
antipneumocysti
drug
prophylaxi
previou
medic
histori
clinic
laboratori
featur
suggest
system
immunosuppress
ie
recurr
oral
thrush
longstand
fever
unknown
caus
clinic
aid
blood
count
cellsml
henc
center
advoc
use
empir
therapi
hivinfect
patient
seen
symptom
chest
radiograph
blood
ga
abnorm
typic
mild
pcp
without
need
bronchoscopi
invas
measur
reserv
atyp
radiograph
present
fail
respond
empir
therapi
day
deterior
stage
clinician
north
america
unit
kingdom
would
seek
obtain
confirm
diagnosi
everi
case
suspect
pcp
practic
strategi
seem
equal
effect
although
number
caveat
born
mind
empir
treatment
given
pcp
patient
pcp
typic
take
day
show
clinic
sign
improv
bronchoscop
proven
diagnosi
ensur
treatment
given
correct
particularli
first
day
therapi
may
well
toler
addit
diagnosi
pcp
implic
infect
individu
may
influenc
decis
start
either
haart
antipneumocysti
prophylaxi
final
empir
therapi
requir
patient
maxim
adher
treatment
nonresolut
symptom
may
seen
failur
therapi
rather
complianc
molecular
biolog
techniqu
pcr
increasingli
use
diagnosi
respiratori
diseas
two
exampl
dna
amplif
loci
p
jirovecii
tuberculosi
genom
advantag
molecular
method
diagnosi
may
made
use
sampl
readili
obtain
bal
fluid
ie
expector
sputum
nasopharyng
secret
also
method
rapid
answer
may
avail
within
work
day
compar
convent
mycobacteri
cultur
may
take
week
despit
encourag
result
research
set
sensit
specif
report
respect
problem
persist
techniqu
appli
routin
diagnost
sampl
includ
extract
nucleic
acid
clinic
materi
crosscontamin
product
previou
assay
clinic
interpret
test
result
current
treatment
individu
infect
hiv
compar
nonhivinfect
gener
popul
increas
likelihood
advers
reaction
therapi
includ
tmpsmx
see
later
antibacteri
antimycobacteri
agent
addit
complex
drug
interact
medic
particularli
compon
haart
institut
therapi
infecti
complic
hivinfect
individu
import
consult
physician
experienc
care
patient
hiv
infect
seek
advic
specialist
pharmacist
main
organ
caus
pneumonia
hivinfect
individu
similar
found
gener
popul
communityacquir
pneumonia
thu
bacteri
pneumonia
hivinfect
patient
treat
similar
manner
hivneg
individu
use
publish
american
thorac
societi
at
british
thorac
societi
bt
guidelin
addit
expert
advic
local
antibiot
resist
pattern
sought
infecti
diseas
microbiolog
colleagu
treatment
usual
begun
empir
basi
caus
organ
identifi
antibiot
sensit
known
clinic
laboratori
prognost
indic
describ
gener
popul
appli
hivinfect
patient
document
present
respons
appropri
antibiot
therapi
usual
rapid
similar
seen
nonhivinfect
individu
earli
relaps
infect
success
treatment
well
describ
hivinfect
patient
presum
pcp
treat
empir
highdos
tmp
smx
infect
either
pneumonia
h
influenza
rather
p
jirovecii
may
also
improv
addit
patient
treat
benzylpenicillin
proven
pneumonia
pneumonia
respond
penicillin
resist
discount
caus
import
consid
whether
second
patholog
process
pcp
copathogen
report
case
pneumonia
institut
treatment
assess
sever
pcp
perform
basi
histori
find
examin
arteri
blood
ga
estim
chest
radiograph
abnorm
patient
stratifi
mild
moder
sever
diseas
tabl
import
drug
unproven
benefit
other
known
ineffect
treatment
sever
diseas
addit
adjuv
glucocorticoid
therapi
may
given
patient
moder
sever
pneumonia
patient
dehydrogenas
defici
receiv
tmpsmx
dapson
primaquin
drug
increas
risk
hemolysi
sever
drug
effect
treatment
pcp
tmp
smx
drug
first
choic
tabl
overal
effect
individu
use
firstlin
therapi
advers
reaction
tmpsmx
common
usual
becom
appar
day
treatment
neutropenia
anemia
patient
rash
fever
biochem
abnorm
liver
function
frequent
advers
reaction
hematolog
toxic
induc
tmpsmx
neither
attenu
prevent
coadministr
folic
folin
acid
furthermor
use
agent
may
associ
reduc
therapeut
success
treatment
tmp
smx
full
blood
count
liver
function
urea
electrolyt
monitor
least
twice
weekli
known
hivinfect
individu
especi
higher
count
high
frequenc
advers
reaction
tmpsmx
optimum
strategi
hivinfect
patient
pcp
becom
intoler
highdos
tmpsmx
establish
mani
physician
treat
minor
rash
often
ad
antihistamin
short
cours
oral
prednisolon
mg
everi
h
reduc
zero
day
treatment
tmpsmx
fail
toler
patient
sever
altern
therapi
avail
see
tabl
combin
clindamycin
primaquin
wide
use
treatment
pcp
whatev
sever
although
licens
unit
kingdom
unit
state
indic
combin
effect
oral
tmpsmx
oral
trimethoprimdapson
treatment
mild
moderatesever
diseas
secondlin
treatment
effect
patient
methemoglobinemia
caus
primaquin
occur
patient
mg
four
time
daili
primaquin
use
rather
mg
four
time
daili
likelihood
methemoglobinemia
reduc
diarrhea
develop
patient
receiv
clindamycin
occur
stool
sampl
analyz
presenc
clostridium
difficil
toxin
oral
combin
effect
oral
tmpsmx
oral
clindamycin
plu
primaquin
see
earlier
treatment
mild
moderatesever
pcp
combin
shown
effect
patient
sever
pcp
patient
experi
methemoglobinemia
caus
dapson
usual
asymptomat
one
half
patient
mild
hyperkalemia
mmoll
caus
trimethoprim
methotrex
analog
trimetrex
given
intraven
togeth
folin
acid
rescu
protect
human
cell
trimetrexateinduc
toxic
patient
moder
regimen
recommend
cdc
nihidsa
wide
use
usa
methylprednisolon
iv
dose
given
prednisolon
methylprednisolon
prednisolon
iv
day
iv
day
g
po
reduc
day
nb
none
regimen
adjuv
glucocorticoid
therapi
compar
prospect
clinic
trial
sever
diseas
trimetrexatefolin
acid
less
effect
highdos
tmpsmx
seriou
treatmentlimit
hematolog
toxic
occur
less
frequent
trimetrexatefolin
acid
atovaquon
licens
treatment
mild
moderatesever
pcp
patient
intoler
tmp
smx
tablet
formul
longer
avail
drug
less
effect
better
toler
tmpsmx
intraven
pentamidin
treatment
mild
moderatesever
pcp
see
tabl
data
prospect
studi
compar
liquid
formul
better
bioavail
treatment
regimen
common
advers
reaction
includ
rash
fever
nausea
vomit
constip
absorpt
atovaquon
increas
taken
food
intraven
pentamidin
seldom
use
treatment
mild
moderatesever
pcp
toxic
intraven
pentamidin
may
use
patient
sever
pcp
despit
toxic
agent
fail
see
tabl
nephrotox
develop
almost
patient
given
intraven
pentamidin
indic
elev
serum
creatinin
leukopenia
develop
approxim
half
symptomat
hypotens
nausea
vomit
hypoglycemia
occur
approxim
patient
given
long
halflif
drug
may
occur
sever
day
discontinu
treatment
pancreat
also
recogn
side
effect
patient
moder
sever
pcp
adjuv
glucocorticoid
therapi
reduc
risk
respiratori
failur
half
risk
death
one
third
see
tabl
glucocorticoid
given
hivinfect
patient
confirm
suspect
pcp
pao
kpa
mmhg
aao
kpa
mmhg
oral
intraven
adjunct
therapi
given
time
within
h
start
specif
antip
jirovecii
therapi
clearli
patient
treatment
commenc
presumpt
basi
pend
confirm
diagnosi
prospect
studi
adjuv
glucocorticoid
shown
benefit
patient
mild
pcp
howev
would
difficult
demonstr
given
surviv
case
approach
standard
treatment
patient
mild
pcp
may
treat
oral
tmpsmx
outpati
abl
manag
home
will
attend
outpati
clinic
regular
review
clinic
radiograph
evid
recoveri
patient
intoler
oral
tmpsmx
despit
clinic
recoveri
either
treatment
given
intraven
treatment
may
chang
oral
clindamycin
plu
primaquin
patient
moder
sever
pcp
hospit
given
intraven
tmpsmx
intraven
clindamycin
oral
primaquin
plu
adjuv
steroid
patient
moder
sever
diseas
show
clinic
radiograph
respons
day
therapi
may
switch
oral
tmpsmx
complet
remain
day
treatment
patient
fail
respond
within
day
deterior
time
receiv
tmpsmx
treatment
chang
clindamycin
primaquin
trimetrex
plu
folin
acid
deterior
patient
receiv
antip
jirovecii
therapi
may
occur
sever
reason
tabl
ascrib
deterior
treatment
failur
consid
chang
therapi
altern
evalu
care
also
import
consid
treat
copathogen
present
bal
fluid
perform
bronchoscopi
diagnosi
made
empir
repeat
procedur
carri
open
lung
biopsi
confirm
diagnosi
correct
center
advoc
admiss
icu
pcp
respiratori
failur
acut
sever
deterior
bronchoscopi
prognosi
sever
pcp
circumst
improv
past
decad
like
greater
understand
success
gener
icu
manag
respiratori
failur
acut
respiratori
distress
syndrom
ard
rather
specif
improv
pcp
care
factor
associ
poor
outcom
includ
increas
patient
age
need
mechan
ventil
develop
pneumothorax
latter
reflect
associ
complic
pcp
well
subsequ
difficulti
success
mechan
ventil
individu
treatment
hivrel
mycobacteri
diseas
complex
individu
take
prolong
cours
rel
toxic
agent
also
antimycobacteri
drug
side
effect
similar
prescrib
develop
world
isoniazidrel
peripher
neuropathi
rare
hivneg
subject
take
pyridoxin
nucleosid
revers
transcriptas
inhibitor
rti
didanosin
stavudin
less
frequent
use
unit
state
unit
kingdom
remain
mainstay
haart
develop
world
also
caus
pain
peripher
neuropathi
complic
develop
patient
stavudin
isoniazid
coadminist
rash
fever
biochem
hepat
common
advers
event
rifamycin
pyrazinamid
isoniazid
occur
frequent
patient
tuberculosi
hiv
infect
hepat
c
coinfect
nonnucleosid
rti
drug
eg
nevirapin
similar
toxic
profil
treatment
hiv
tuberculosi
coadminist
ascrib
caus
may
problemat
drugdrug
interact
medic
use
treat
tuberculosi
hiv
infect
occur
common
pathway
metabol
hepat
cytochrom
enzym
system
rifampin
potent
induc
enzym
rifabutin
less
may
result
subtherapeut
level
nonnucleosid
rti
pi
antiretrovir
drug
potenti
inadequ
suppress
hiv
replic
develop
resist
hiv
addit
pi
class
antiretrovir
drug
inhibit
metabol
rifamycin
lead
increas
plasma
concentr
associ
increas
drug
toxic
nonnucleosid
rti
drug
induc
enzym
pathway
coadministr
rifabutin
efavirenz
requir
increas
dose
rifabutin
compens
increas
metabol
induc
efavirenz
see
later
optim
durat
treatment
tuberculosi
use
rifamycinbas
regimen
patient
hiv
infect
unknown
current
recommend
joint
tuberculosi
committe
bt
atscdcinfecti
diseas
societi
north
america
idsa
treat
tuberculosi
hivinfect
patient
way
gener
popul
ie
month
drugsensit
pulmonari
tb
addit
atscdcidsa
guidelin
recommend
treatment
extend
month
cavit
origin
radiograph
continu
sign
posit
cultur
month
therapi
recent
work
highlight
increas
risk
develop
rifampin
monoresist
hivinfect
individu
treatment
especi
intermitt
regimen
use
may
aris
lack
efficaci
drug
present
combin
eg
intermitt
isoniazid
henc
daili
medic
regimen
recommend
close
supervis
hivposit
patient
rememb
although
rifabutin
usual
given
three
time
week
ritonavirboost
proteas
inhibitor
seem
achiev
adequ
rifamycin
level
report
lead
rifamycin
resist
patient
appropri
adher
directli
observ
therapi
dot
import
although
fairli
laborintens
strategi
support
world
health
organ
best
time
start
therapi
patient
treat
tuberculosi
unknown
decis
analys
show
earli
treatment
antiretrovir
therapi
lead
mark
reduct
opportunist
diseas
balanc
risk
need
discontinu
antituberculosi
therapi
hiv
therapi
drug
toxic
drugdrug
interact
iri
report
like
treatment
start
time
pragmat
delay
start
antiretrovir
therapi
simplifi
patient
manag
may
reduc
prevent
advers
drug
reaction
drugdrug
interact
may
also
reduc
risk
iri
basi
current
evid
patient
count
cellsml
low
risk
hiv
diseas
progress
death
month
treatment
tuberculosi
patient
count
close
monitor
antiretrovir
therapi
may
defer
treatment
tuberculosi
complet
patient
count
cellsml
mani
center
current
delay
start
antiretrovir
therapi
first
month
treatment
tuberculosi
complet
patient
given
concomit
pcp
prophylaxi
patient
count
cellsml
antiretrovir
therapi
start
soon
possibl
begin
treatment
tuberculosi
base
evid
show
signific
shortterm
risk
hiv
diseas
progress
death
patient
group
antiretrovir
therapi
delay
two
option
exist
start
antiretrovir
therapi
patient
alreadi
treat
tuberculosi
first
rifampinbas
regimen
continu
antiretrovir
therapi
commenc
exampl
combin
two
nucleosid
rti
nonnucleosid
rti
efavirenz
patient
weigh
kg
efavirenz
dose
often
increas
mg
daili
compens
rifampininduc
metabol
efavirenz
altern
rifampin
stop
rifabutin
start
antiretrovir
therapi
given
combin
two
nucleosid
rti
drug
either
singl
ritonavirboost
pi
nonnucleosid
rti
dose
rifabutin
adjust
take
account
pharmacokinet
effect
coadminist
drug
boost
pi
usual
prescrib
dose
mg
three
time
weekli
efavirenz
increas
mg
day
advent
antiretrovir
therapi
recogn
tuberculosi
physician
patient
appar
respond
antimycobacteri
treatment
would
sometim
short
period
clinic
deterior
develop
paradox
reaction
face
overal
treatment
respons
seen
interest
probabl
immunebas
phenomenon
gener
littl
consequ
widespread
introduct
haart
led
increas
awar
clinician
similar
gener
sever
event
hivinfect
individu
context
hiv
term
iri
immun
reconstitut
diseas
present
number
way
rang
opportunist
condit
perhap
common
similar
paradox
reaction
initi
antiretrovir
therapi
patient
treat
tuberculosi
exampl
aris
return
origin
develop
new
symptom
sign
often
system
natur
may
associ
mark
radiograph
chang
exampl
includ
fever
dyspnea
lymphadenopathi
effus
parenchym
pulmonari
infiltr
expans
cerebr
tuberculoma
form
iri
seen
frequent
mycobacteria
commonli
tuberculosi
mac
fungi
notabl
cryptococcu
virus
hepat
herp
virida
iri
develop
one
third
hivinfect
patient
treat
tuberculosi
antiretrovir
therapi
start
median
onset
tuberculosisrel
iri
approxim
week
begin
antituberculosi
treatment
week
commenc
haart
seem
like
patient
dissemin
tuberculosi
henc
presum
antigen
present
well
potenti
signific
inflammatori
reaction
lower
baselin
blood
count
rapid
fall
hiv
load
well
larg
increas
count
respons
haart
may
also
predict
iri
relationship
earli
use
haart
low
blood
count
suggest
care
must
taken
start
antiretrovir
patient
tb
site
rapid
expans
inflammatori
mass
could
life
threaten
exampl
would
includ
cerebr
pericardi
peritrach
diseas
figur
import
note
iri
current
diagnosi
exclus
laboratori
test
avail
assist
made
progress
multi
drugresist
tuberculosi
poor
drug
adher
either
antituberculosi
antiretrovir
agent
drug
absorpt
altern
patholog
process
exclud
explan
present
criteria
drawn
seek
provid
clinic
diagnost
criteria
tabl
mechan
lead
iri
unclear
due
failur
treatment
tuberculosi
anoth
diseas
process
anyth
like
repres
exuber
uncontrol
respons
mycobacteri
antigen
dead
live
organ
current
treatment
includ
nonsteroid
antiinflammatori
drug
glucocorticoid
latter
undoubtedli
effect
although
lead
hyperglycemia
hypertens
recent
preliminari
data
suggest
leukotrien
receptor
antagonist
montelukast
may
benefit
iri
drug
unlicens
indic
recurr
aspir
lymph
node
effus
may
also
need
although
iri
often
selflimit
may
persist
sever
month
rare
temporari
discontinu
antiretrovir
therapi
requir
situat
may
precipit
fall
count
patient
risk
opportunist
infect
attent
also
focus
possibl
concernth
form
iri
refer
unmask
phenomenon
individu
presum
latent
tuberculosi
infect
start
haart
system
activ
often
infecti
tuberculosi
develop
within
period
although
like
patient
diseas
would
present
time
anyway
report
case
may
fact
repres
ascertain
bia
current
view
real
repres
advers
effect
haart
given
peopl
risk
live
countri
limit
facil
prehaart
screen
major
implic
antiretrovir
therapi
rollout
program
resourcepoor
area
combin
antimycobacteri
therapi
cure
mac
infect
commonli
use
regimen
oral
rifabutin
mg
daili
oral
ethambutol
mgkg
daili
oral
clarithromycin
mg
daili
everi
h
clarithromycin
use
oral
rifabutin
mg
daili
giventh
lower
dose
adjust
yet
drugdrug
interact
use
three
drug
impact
overal
outcom
although
reduc
risk
resist
possibl
enhanc
earli
mycobacteri
kill
patient
sever
compromis
symptom
intraven
amikacin
mgkg
daili
week
also
given
trough
blood
level
must
measur
ensur
toxic
accumul
amikacin
occur
fluoroquinolon
moxifloxacin
levofloxacin
may
extrem
use
good
antimycobacteri
activ
limit
side
effect
present
mani
agent
licens
indic
given
concern
xdr
tuberculosi
import
ensur
patient
adher
treatment
henc
reduc
risk
fluoroquinolon
resist
develop
frequent
use
regimen
includ
rifampin
isoniazid
ethambutol
convent
dose
drug
given
mouth
treatment
regimen
fungal
infect
complic
hiv
infect
shown
tabl
initi
treatment
cryptococc
infect
high
likelihood
relaps
infect
henc
lifelong
secondari
prevent
therapi
need
unless
antiretrovir
therapi
commenc
result
sustain
improv
count
cellsml
suppress
hiv
load
peripher
blood
secondari
prophylaxi
often
oral
fluconazol
mg
four
time
daili
mycobacteri
diseas
late
iri
event
occur
month
even
year
investig
exclud
activ
diseas
condit
oral
itraconazol
mg
twice
daili
current
treatment
choic
dose
adjust
achiev
blood
trough
drug
level
standard
lowest
effect
concentr
data
impact
antiretrovir
therapi
base
decis
discontinu
secondari
prophylaxi
treatment
infect
difficult
initi
treatment
amphotericin
b
itraconazol
fluconazol
may
given
longterm
suppress
overal
prognosi
poor
mortal
rate
despit
therapi
data
impact
antiretrovir
therapi
base
decis
discontinu
secondari
prophylaxi
oral
itraconazol
replac
amphotericin
b
treatment
choic
p
marneffei
infect
apart
subgroup
acut
unwel
fluconazol
less
effect
itraconazol
initi
treatment
lifelong
suppress
therapi
itraconazol
need
data
impact
antiretrovir
therapi
base
decis
discontinu
secondari
prophylaxi
treatment
regimen
shown
tabl
combin
sulfadiazin
pyrimethamin
regimen
choic
gondii
infect
frequent
doselimit
side
effect
rash
fever
adequ
hydrat
must
maintain
avoid
risk
sulfadiazin
crystalluria
obstruct
uropathi
altern
regimen
given
tabl
treatment
complet
lifelong
mainten
necessari
prevent
relaps
unless
antiretrovir
therapi
achiev
adequ
immun
restor
blood
count
cellsml
undetect
hiv
load
viscer
leishmaniasi
usual
treat
liposom
amphotericin
b
although
still
associ
high
rate
relaps
secondlin
therapi
firstlin
resourcepoor
environ
use
sodium
stiboglucon
see
tabl
phenomena
tempor
associ
start
haart
includ
limit
new
enlarg
lymphadenopathi
cold
abscess
focal
tissu
involv
new
worsen
central
nervou
system
diseas
new
worsen
radiolog
featur
tuberculosi
new
worsen
seros
pleural
effus
ascit
pericardi
effus
arthriti
new
worsen
constitut
symptom
fever
night
sweat
andor
weight
loss
retrospect
review
indic
clinic
radiolog
deterior
occur
chang
made
tuberculosi
treatment
c
immun
restor
eg
rise
lymphocyt
count
respons
haart
fall
hiv
viral
load
respons
haart
altern
diagnos
exclud
progress
underli
infect
treatment
failur
due
drug
resist
mdr
xdr
treatment
failur
poor
adher
advers
drug
reaction
anoth
diagnosi
coexist
eg
nonhodgkin
lymphoma
treatment
choic
ivermectin
risk
treatment
failur
thiabendazol
hivinfect
individu
higher
nonhivinfect
patient
cytomegaloviru
pneumon
treat
intraven
ganciclovir
mgkg
everi
h
day
druginduc
neutropenia
manag
granulocyt
colonystimul
factor
center
use
valganciclovir
oral
formul
ganciclovir
dose
mg
oral
everi
h
treat
cmv
pneumon
side
effect
manag
ganciclovir
data
demonstr
efficaci
cidofovir
treatment
cmv
pneumon
agent
use
secondlin
therapi
mani
center
phosphonoform
foscarnet
use
treatment
cmv
endorgan
diseas
eg
pneumon
although
extens
toxic
profil
also
moder
effect
antiretrovir
agent
effect
occasion
use
adjunct
control
nonrespons
viral
infect
within
past
year
drug
therapi
radic
alter
depressingli
predict
natur
progress
hiv
infect
combin
specif
opportunist
infect
prophylaxi
antiretrovir
therapi
reduc
incid
mortal
associ
common
condit
observ
north
american
mac
cohort
demonstr
risk
pcp
individu
blood
count
cellsml
reduc
almost
fourfold
specif
prophylaxi
haart
taken
howev
common
condit
prevent
less
treatabl
ill
may
aris
initi
impact
p
jirovecii
prophylaxi
reduct
incid
pcp
expens
increas
case
dissemin
mac
infect
cmv
infect
esophag
candidiasi
wast
syndrom
new
prophylact
therapi
target
condit
associ
high
morbid
mortal
particular
mac
improv
surviv
becom
appar
specif
infect
prophylaxi
may
also
confer
protect
agent
cross
prophylaxi
particularli
seen
use
tmpsmx
pneumocysti
also
provid
cover
cerebr
toxoplasmosi
sever
common
bacteri
infect
although
pneumonia
macrolid
mac
infect
reduc
incid
bacteri
diseas
also
pcp
use
larg
amount
antibiot
rais
possibl
futur
widespread
drug
resist
clearli
concern
recent
report
suggest
inde
part
world
incid
pneumococc
tmpsmx
resist
rise
current
prevent
therapi
pertin
lung
diseas
focu
p
jirovecii
mac
tuberculosi
certain
bacteria
tabl
numer
studi
demonstr
greatli
increas
risk
subject
take
adequ
drug
therapi
blood
count
cellsml
clinic
symptom
also
independ
risk
factor
pcp
henc
current
guidelin
recommend
lifelong
prophylaxi
p
jirovecii
hivinfect
adult
prior
pcp
count
cellsml
constitut
symptom
document
oral
thrush
fever
unknown
caus
c
persist
week
clinic
aid
import
secondari
prophylaxi
ie
use
episod
pcp
becom
clear
histor
data
indic
risk
relaps
first
month
infect
increas
system
local
immun
occur
haart
led
sever
studi
evalu
need
prolong
prophylaxi
individu
sustain
elev
blood
count
low
hiv
rna
load
summari
seem
primari
secondari
pcp
prophylaxi
discontinu
count
cellsml
month
caveat
patient
low
undetect
hiv
rna
load
percentag
stabl
rise
individu
plan
continu
haart
long
term
good
adher
risk
pcp
recurr
real
count
fall
cellsml
happen
pcp
prophylaxi
restart
similar
algorithm
success
use
major
infect
except
tuberculosi
reli
estim
gener
blood
count
clinic
diseas
highli
unlik
exampl
secondari
prophylaxi
mac
may
discontinu
blood
count
consist
cellsml
gener
guidelin
howev
patient
must
assess
individu
basi
treatment
strategi
tmpsmx
drug
choic
prophylaxi
tabl
advantag
highli
effect
primari
secondari
prophylaxi
risk
pcp
drug
respect
cheap
taken
oral
act
system
provid
crossprophylaxi
infect
toxoplasmosi
salmonella
speci
staphylococcu
speci
h
influenza
main
disadvantag
advers
reaction
common
see
earlier
occur
individu
take
prophylact
dose
standard
dose
tmpsmx
one
doublestrength
tablet
mg
trimethoprim
mg
sulfamethoxazol
per
day
regimen
tri
includ
one
doublestrength
tablet
three
time
weekli
one
singlestrength
tablet
per
day
gener
use
primari
prophylaxi
regimen
toler
well
better
standard
seem
efficaci
one
doublestrength
tablet
per
day
data
less
clear
secondari
prophylaxi
subject
much
higher
risk
recurr
pcp
attempt
desensit
patient
intoler
tmp
smx
met
success
patient
toler
tmpsmx
dapson
safe
inexpens
altern
studi
number
trial
primari
secondari
prophylaxi
effect
oral
dose
mgday
combin
pyrimethamin
mg
three
time
weekli
provid
degre
crossprophylaxi
toxoplasmosi
start
dapson
patient
test
dehydrogenas
defici
nebul
pentamidin
larg
fallen
use
prophylact
agent
despit
better
toler
similar
efficaci
tmpsmx
primari
prevent
therapi
howev
breakthrough
rate
higher
subject
lower
count
ie
cellsml
take
secondari
prophylaxi
disadvantag
includ
equip
cost
complex
alveolar
deposit
crucial
henc
nebul
system
use
import
risk
transmiss
respiratori
diseas
eg
tuberculosi
patient
staff
nebul
procedur
alter
clinic
present
pcp
pentamidin
increas
frequenc
radiograph
upper
zone
shadow
increas
incid
pneumothorax
lack
system
protect
pneumocysti
infecti
agent
also
acut
bronchoconstrict
effect
nebul
longterm
followup
studi
demonstr
signific
neg
effect
lung
function
atovaquon
oral
suspens
use
secondlin
prophylact
agent
subject
intoler
tmpsmx
seem
similar
efficaci
dapson
given
togeth
weekli
pyrimethamin
reduc
incid
side
effect
frequent
rash
fever
gastrointestin
disturb
azithromycin
use
mani
center
thirdlin
prophylact
agent
given
dose
mg
weekli
may
provid
protect
bacteri
infect
well
mac
low
blood
count
cellsml
current
best
laboratori
predictor
prophylaxi
failur
particularli
surpris
given
median
blood
count
subject
prophylaxi
pcp
develop
cellsml
persist
fever
unknown
caus
import
clinic
risk
factor
pcp
use
prevent
therapi
tmp
smx
significantli
reduc
chanc
develop
pneumocysti
therefor
vital
subject
vulner
encourag
use
drug
regular
basi
pspc
cohort
studi
reveal
subject
count
cellsml
receiv
form
pcp
prophylaxi
effect
safe
ie
replic
incompet
bacteri
vaccin
avail
would
expect
wide
use
prevent
hivrel
diseas
fact
uptak
pneumococc
h
influenza
type
b
hib
vaccin
poor
current
estim
former
infect
popul
recommend
vaccin
one
reason
may
protect
confer
vaccin
gener
popul
seen
immunosuppress
hivinfect
individu
reflect
inabl
gener
adequ
memori
bcell
respons
especi
subject
count
cellsml
howev
north
america
cdcidsa
recommend
pneumococc
vaccin
singl
dose
soon
hiv
infect
diagnos
booster
year
individu
blood
count
cellsml
subsequ
increas
haart
sever
studi
show
pneumococc
immun
reduc
risk
invas
pneumococc
infect
popul
seem
case
develop
world
set
vaccin
ineffect
invas
noninvas
pneumococc
diseas
overal
incid
pneumonia
increas
infect
h
influenza
type
b
much
less
common
hivinfect
adult
therefor
immun
hib
vaccin
routin
recommend
littl
evid
suggest
high
frequenc
bacteri
infect
hiv
popul
relat
bacteri
colon
therefor
continu
antibiot
rare
indic
although
tmpsmx
macrolid
clarithromycin
azithromycin
given
longterm
prophylaxi
opportunist
infect
shown
reduc
incid
bacteri
pneumonia
sinusitisot
media
infecti
diarrhea
use
tmpsmx
also
confer
surviv
advantag
mani
studi
perform
resourcepoor
set
littl
evid
howev
tmpsmx
protect
pneumococc
infect
interact
hiv
tuberculosi
fundament
import
annual
risk
develop
clinic
tuberculosi
given
individu
estim
ie
similar
nonhivinfect
subject
lifetim
risk
hivinfect
individu
pulmonari
tuberculosi
less
like
smear
posit
hivneg
counterpart
although
still
transmit
tuberculosi
thu
within
commun
tuberculosi
prevent
involv
case
find
treatment
activ
diseas
well
specif
prophylact
drug
therapi
expos
possibl
hivposit
subject
make
everi
effort
avoid
encount
tuberculosi
eg
work
homeless
shelter
health
care
facil
one
problem
standard
method
tuberculosi
contact
trace
hiv
infect
tuberculin
skin
test
result
chest
radiolog
may
unreli
howev
absenc
bacillu
bcg
immun
posit
ppd
eg
mm
indur
tuberculin
unit
indic
greatli
increas
risk
compar
nonanerg
ppdneg
hivinfect
subject
futur
activ
diseas
chanc
hivinfect
subject
may
contract
dissemin
infect
given
bcg
mean
exclud
activ
infect
option
circumst
use
prevent
drug
regimen
option
includ
least
month
isoniazid
togeth
pyridoxin
prevent
peripher
neuropathi
safe
well
toler
although
complianc
problem
especi
regimen
longer
month
dot
may
need
institut
eg
mg
isoniazid
twice
weekli
littl
evid
suggest
singleag
regimen
lead
isoniazid
resist
probabl
reflect
low
mycobacteri
load
present
individu
attempt
shorten
length
treatment
latent
infect
produc
variabl
result
recent
studi
use
rifampin
pyrazinamid
shortcours
prophylaxi
month
effect
month
isoniazid
hivcoinfect
individu
although
associ
fatal
hepatotox
almost
exclus
hivneg
popul
henc
current
favor
use
liver
function
close
monitor
recommend
regimen
given
patient
preexist
liver
diseas
eg
alcohol
viral
hepat
rifampin
use
subject
take
pi
may
also
limit
widespread
applic
twodrug
regimen
appli
combin
isoniazid
rifampin
taken
least
month
also
effect
hivneg
individu
altern
protocol
also
exist
subject
thought
resist
firstlin
prophylact
agent
wide
clinic
evalu
recommend
hivinfect
subject
close
contact
activ
case
tuberculosi
also
receiv
prophylaxi
littl
evid
suggest
anergi
confer
increas
risk
develop
clinic
diseas
howev
patient
bcg
neg
skin
test
start
haart
may
benefit
regular
skin
test
studi
suggest
cutan
respons
may
return
increas
count
may
help
identifi
newli
infect
individu
requir
prophylaxi
popul
preval
tuberculosi
low
bcg
may
given
childhood
adolesc
eg
unit
kingdom
valu
ppd
test
limit
arbitrari
cutoff
mm
tuberculin
reaction
use
defin
receiv
prevent
therapi
introduct
immunebas
blood
test
accur
distinguish
bcg
vaccin
tuberculosi
infect
may
help
screen
evid
latent
tuberculosi
two
current
avail
commerci
test
use
fairli
specif
mycobacteri
antigen
respons
consequ
product
detect
interferong
need
reason
intact
function
mean
may
fact
less
use
hiv
infect
especi
subject
low
blood
count
possibl
greatest
risk
develop
activ
tuberculosi
secondari
tuberculosi
prophylaxi
may
import
studi
indic
high
rate
relaps
endem
area
specif
guidelin
exist
although
month
isoniazid
rifampin
full
treatment
cours
show
greatli
reduc
risk
relaps
within
subsequ
year
whether
enough
prevent
clinic
diseas
may
also
aris
reinfect
area
high
tuberculosi
preval
without
concomit
antiretrovir
therapi
unclear
develop
world
secondari
prophylaxi
usual
recommend
use
haart
also
reduc
risk
tuberculosi
endem
area
work
south
africa
indic
benefici
patient
advanc
diseas
lead
reduct
rr
least
data
north
america
indic
prevent
dissemin
mac
infect
effect
surviv
reduct
mortal
rate
subject
take
clarithromycin
us
guidelin
advis
prophylaxi
macrolid
either
clarithromycin
mg
oral
twice
per
day
azithromycin
mg
oral
week
hivinfect
individu
blood
count
cellsml
europ
preval
dissemin
mac
infect
probabl
lower
perhap
previou
bcg
vaccin
may
less
relev
surveil
cultur
blood
may
costeffect
atrisk
hiv
popul
low
count
routin
stool
sputum
cultur
probabl
add
much
strategi
dissemin
mac
much
common
isol
organ
diseas
singleag
prophylaxi
may
lead
antibiot
resist
seem
reduc
addit
second
drug
rifabutin
prophylact
regimen
latter
secondlin
prophylact
agent
larg
result
rather
wors
protect
effect
advers
interact
profil
pi
mention
earlier
individu
sustain
rise
count
cellsml
month
safe
discontinu
prophylaxi
sever
clinic
laboratori
featur
prognost
signific
hivinfect
individu
pcp
box
sever
score
basi
serum
ldh
level
aao
percentag
neutrophil
bal
fluid
predict
surviv
reason
accur
highest
score
indic
worst
outcom
worker
shown
increas
age
year
lead
increas
mortal
ratein
part
result
late
unsuspect
diagnosi
overal
mortal
rate
episod
pcp
approxim
chang
sinc
advent
haart
among
individu
access
haart
postpcp
surviv
improv
median
surviv
pcp
month
risen
month
introduct
haart
led
improv
surviv
period
year
month
without
access
haart
andor
prophylaxi
surviv
postpcp
unfortun
remain
poor
gener
mortal
bacteri
respiratori
infect
hivinfect
individu
similar
seen
gener
popul
clinic
laboratori
marker
diseas
sever
defin
adult
gener
popul
eg
describ
at
bt
guidelin
manag
communityacquir
pneumonia
adult
appli
hivinfect
patient
confus
rais
respiratori
rate
abnorm
renal
function
low
blood
pressur
recurr
pneumonia
common
report
case
may
lead
chronic
pulmonari
diseas
see
earlier
although
tuberculosi
normal
respond
standard
multipledrug
therapi
work
africa
highlight
increas
mortal
rate
hivinfect
compar
nonhivinfect
individu
relationship
also
describ
mortal
declin
blood
count
hivinfect
patient
count
cellsml
mortal
rate
compar
count
cellsml
compar
hivinfect
individu
without
tuberculosi
main
effect
mortal
seen
patient
higher
count
cellsml
rel
risk
death
three
time
nontubercul
popul
sever
casecontrol
studi
indic
absenc
effect
treatment
macinfect
patient
reduc
surviv
compar
blood
levelmatch
control
subject
approxim
month
vs
month
respect
current
avail
treatment
regimen
may
reduc
differ
although
sever
anemia
seem
independ
predictor
mortal
presenc
cmv
bal
fluid
also
contain
p
jirovecii
relat
outcom
see
earlier
mortal
rate
month
bronchoscopi
greater
cmv
detect
bronchoscopi
howev
cmv
recov
sole
pathogen
impact
surviv
effect
antiretrovir
therapi
opportunist
infect
introduct
haart
togeth
wide
avail
accur
method
determin
plasma
rna
viral
load
led
profound
chang
clinic
practic
hiv
outcom
although
still
case
respiratori
diseas
remain
nonhiv
infect
background
level
particular
bacteri
pneumonia
tb
lung
cancer
common
despit
appar
effect
haart
hivinfect
subject
overal
data
indic
clinic
progress
rare
subject
abl
adher
rigor
least
antiretrovir
drug
regimen
mortal
rate
fallen
almost
condit
seem
damag
immun
system
clinic
signific
extent
reconstitut
period
least
sever
year
henc
clinician
need
consid
opportunist
infect
malign
within
diagnost
workup
also
effect
drug
therapi
side
effect
profil
haart
eg
metabol
mitochondri
toxic
liver
damag
neuropsychiatr
disord
well
larg
number
drugdrug
interact
make
complex
area
manag
best
exampl
hivrel
tuberculosi
overlap
toxic
pharmacolog
interact
iri
common
research
need
address
area
studi
inform
decis
start
haart
patient
alreadi
antituberculosi
medic
work
need
focu
understand
box
prognost
factor
associ
poor
outcom
pneumocysti
jirovecii
pneumonia
admiss
patient
age
previou
knowledg
hiv
statu
tachypnea
respiratori
rate
second
subsequ
episod
pneumocysti
jirovecii
pneumonia
poor
oxygen
pao
kpa
mmhg
aao
kpa
mmhg
low
serum
albumin
gdl
low
hemoglobin
gdl
peripher
blood
leukocytosi
l
elev
serum
lactat
dehydrogenas
level
iul
count
cellsml
mark
chest
radiograph
abnormalitiesdiffus
bilater
interstiti
infiltr
without
alveolar
consolid
medic
comorbid
eg
pregnanc
bronchoscopi
bronchoalveolar
lavag
fluid
detect
copatholog
cmv
bacteria
b
neutrophilia
detect
pulmonari
kaposi
sarcoma
serum
lactat
dehydrogenas
level
remain
elev
develop
pneumothorax
high
apach
ii
score
admiss
icu
need
mechan
ventil
full
pulmonari
immun
restor
may
reflect
abnorm
innat
immun
respons
current
poorli
describ
hiv
infect
despit
benefit
haart
like
long
term
mani
patient
progress
sever
diseas
current
littl
research
area
research
focu
correl
clinic
laboratori
find
exampl
would
assess
risk
individu
develop
activ
tuberculosi
clear
much
excess
mortal
hivtuberculosi
coinfect
occur
earli
hiv
infect
thu
test
devis
indic
latent
tuberculosi
infect
therefor
like
clinic
diseas
develop
step
taken
prevent
ill
discuss
previous
immunebas
test
shown
promis
immunocompet
individu
tuberculosi
infect
refin
work
consist
patient
hiv
infect
reason
cost
possibl
target
risk
futur
tuberculosi
tuberculosi
unmask
start
haart
role
test
would
rapid
diagnosi
activ
tuberculosi
common
face
patient
nonspecif
symptom
wide
differenti
diagnosi
often
treatment
multipl
empir
quantit
test
would
help
resolv
dilemma
indic
chanc
condit
caus
particular
diseas
exampl
would
patient
endem
tuberculosi
area
low
count
pulmonari
central
nervou
system
diseas
tuberculosi
toxoplasmosi
cryptococcosi
viral
bacteri
infect
test
tuberculosi
would
also
distinguish
differ
state
old
treat
old
inact
old
latent
activ
although
insurmount
present
possibl
rapid
diagnost
assay
assess
organ
viabil
also
import
clinician
receiv
earli
feedback
whether
treatment
produc
suitabl
kill
effect
therapi
tailor
individu
enabl
regimen
dose
adjust
need
remov
element
concern
often
present
patient
slow
respond
exampl
would
treatment
pcp
mycobacteri
diseas
frequenc
bacteri
infect
often
recurr
attend
sequela
make
effect
strategi
vaccin
import
prioriti
uncertain
differenti
respons
vaccin
even
unit
state
african
american
seem
deriv
benefit
white
need
research
togeth
emphasi
identifi
local
immun
respons
present
lung
individu
bacteri
infect
may
clinic
indistinguish
pathogen
two
third
respiratori
infect
formal
diagnos
need
improv
method
assist
use
rapid
antigen
test
may
one
way
forward
especi
given
high
incid
potenti
fatal
bacteremia
present
popul
maximum
benefit
need
use
system
simpl
cheap
henc
suitabl
resourcerich
resourcepoor
countri
tuberculosi
global
import
hivrel
pathogen
strategi
control
prevent
vital
ensur
million
peopl
becom
coinfect
go
clinic
diseas
develop
rapid
diagnost
critic
encourag
report
simpl
cheap
method
mod
diagnos
tuberculosi
provid
resist
data
field
set
see
earlier
argu
largescal
roll
evalu
beyond
public
health
measur
dot
fixeddos
combin
drug
case
manag
educ
research
need
improv
current
drug
therapi
longact
prepar
rifapentin
show
promis
problem
rifampicin
monoresist
demonstr
still
much
work
done
first
time
mani
year
sever
antimycobacteri
drug
variou
stage
clinic
trial
promis
sever
novel
mechan
action
global
allianc
stop
tb
campaign
crucial
regard
fluoroquinolon
moxifloxacin
gatifloxacin
closest
market
potent
drug
consider
abil
kill
also
steril
mycobacteriainfect
site
trial
treatmentshorten
regimen
ongo
worldwid
vaccin
tuberculosi
bcg
understand
wide
use
immunosuppress
hivinfect
popul
howev
safe
vaccin
may
afford
way
protect
larg
part
world
tuberculosi
far
seem
success
vaccin
either
enhanc
replac
primari
protect
effect
bcg
use
immunotherapi
eg
heatkil
mycobacterium
vacca
combin
chemotherapi
disappoint
clinic
trial
newer
method
diagnosi
eg
pcr
test
saliva
may
prove
invalu
quick
easi
diseas
confirm
although
applic
routin
sampl
need
evalu
p
jirovecii
prophylaxi
first
import
hiv
treatment
wide
avail
howev
despit
efficaci
tmpsmx
complianc
remain
problem
regimen
use
gradual
increas
dosag
start
prophylaxi
may
help
one
concern
widespread
use
prophylaxi
resist
start
occur
tmpsmx
report
indic
mutat
p
jirovecii
dihydroptero
synthas
gene
confer
resist
seem
increas
time
although
seem
present
mani
patient
fail
treatment
pcp
tmpsmx
implic
uncertain
could
includ
greater
likelihood
treatment
failur
possibl
worsen
pattern
global
bacteri
drug
resist
hivinfect
popul
develop
world
high
rate
smoke
evid
harm
effect
seen
gener
popul
continu
accru
acceler
cours
obstruct
lung
diseas
cancer
togeth
increas
risk
respiratori
infect
smoker
persuas
argu
case
target
smoke
cessat
hiv
infect
haart
profound
probabl
neg
effect
blood
lipid
insulin
resist
support
need
reduc
smoke
rate
popul
seem
start
see
increas
rate
cardiovascular
diseas
age
popul
natur
histori
hivrel
respiratori
diseas
continu
evolv
haart
newer
therapeut
strategi
made
signific
impact
morbid
mortal
yet
individu
continu
becom
hiv
infect
progress
die
everexpand
rang
condit
p
jirovecii
remain
common
aidsdefin
event
develop
world
wherea
tuberculosi
global
common
caus
death
bacteri
respiratori
infect
far
behind
given
huge
number
individu
hiv
infect
effect
way
manag
diseas
find
simpl
way
treat
hiv
thu
contain
worst
ravag
ill
